ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
The Impact of Intensified CNS-Directed Therapy on Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 11 citations in OpenAlex.
- Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana-Farber Cancer Institute ALL Consortium Study 16-001.Pediatric blood & cancer · 2026Trial
- Baseline Neurocognitive Functioning Among Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana Farber Cancer Institute ALL Consortium Study 16-001.Pediatric blood & cancer · 2025Trial
- JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Factors associated with executive function in children with lymphoma undergoing chemotherapy: A cross-sectional study based on the theory of unpleasant symptoms.Asia-Pacific journal of oncology nursing · 2026Article
- Informing Cancer Education and School Reintegration After Childhood Cancer: Metacognitive, Psychosocial, and School-Participation Indicators.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Review
- Executive function after childhood cancer: Insights from network neuroscience.Neuro-oncology advances · 2026Review
- Multiscale connectivity framework for working memory network in paediatric acute lymphoblastic leukaemia survivors.Brain communications · 2026Article
- Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries.Leukemia · 2024Review
- Acute Lymphoblastic Leukemia with Central Nervous System Involvement-Challenges in Management.Indian journal of pediatrics · 2024Review
- Central nervous system therapy in acute lymphoblastic leukemia: no more, no less.Haematologica · 2023Article
- [Recent research on cognitive impairment in children with acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeFindings from St Jude Total Therapy Study 16 (Total 16) showed early intensification of triple intrathecal therapy (ITT) improved CNS disease control for children with newly diagnosed acute lymphoblastic leukemia (ALL) at the greatest risk of CNS relapse. We examined the impact of this treatment on end-of-therapy neurocognitive outcomes.
methodsBetween 2007 and 2017, 400 (83.5%) of 479 eligible patients treated with Total 16 risk-directed chemotherapy completed protocol-directed neurocognitive testing at the end of therapy. Intensified ITT was defined as ≥ 21 cumulative doses for patients with low-risk ALL (n = 70/194) and ≥ 27 doses for those with standard-to-high risk ALL (n = 81/206).
resultsCompared with age-normative expectations, the overall group had significantly lower estimated intelligence quotient (
conclusionStandard-to-high risk patients treated with intensified ITT are at moderately increased risk for neurocognitive problems. The findings suggest a threshold effect for ITT exposure, which can inform the design of future clinical trials and approaches to neurocognitive monitoring and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.